Full Version
|
Search
The Irish Medicines Board - www.imb.ie
Home
About Us
Consultation
Events
Glossary
Legislation
Links
News
Publications
Recruitment
Register
Safety & Quality
Human Medicines
Veterinary
Medical Devices
Blood, Tissues, Organs
Cosmetics
Patients & Public
Home
»
Publications
»
Ziagen (abacavir sulfate)
Your Selection
[x]
Product
: Human medicines
[x] Remove All Filters
By Audience / Stakeholder Group
All Stakeholders (16)
Healthcare professionals (389)
Industry (148)
Patients and consumers (7)
By Document Type
Corporate & Policy Documents (1)
Direct Healthcare Professional Communication (254)
Fees (2)
Forms & Templates (49)
Guidance (70)
Information Leaflets (5)
Newsletters (91)
Safety Updates & Reports (75)
By Service
Advertising Compliance (1)
Clinical Trials (13)
Controlled Drugs (9)
Exempt Products (1)
Export Certification (12)
Laboratory Approval (2)
Licensing – Medicines (47)
Manufacturing & Wholesale (18)
Medical Devices (1)
Product Classification (6)
Reporting Safety & Quality issues (8)
Ziagen (abacavir sulfate) - Important Safety Information from GlaxoWellcome as approved by the Irish Medicines Board
21 January 2000
Tags:
Human medicines
Healthcare professionals
Direct Healthcare Professional Communication
2000
Please find attached Safety Communication from GlaxoWellcome in respect of Ziagen
« View Publications List
Provide Feedback
RSS Feeds
IMB Publications RSS Feed